Does Orencia Increase Risk of Lung Infections?
Orencia (abatacept) suppresses T-cell activation, weakening immune responses and raising susceptibility to infections, including serious ones in the lungs like pneumonia.[1] Clinical trials and post-marketing data show higher rates of respiratory infections with Orencia compared to placebo. In rheumatoid arthritis studies, upper respiratory infections occurred in 17-19% of Orencia users versus 13-16% in placebo groups, while lower respiratory infections (e.g., pneumonia) hit 4-6% versus 2-3%.[2]
What Do Real-World Studies Show?
Observational data from registries like CORRONA confirm elevated pneumonia risk. A 2019 analysis of over 10,000 RA patients found Orencia users had a 1.5-2-fold higher adjusted incidence of serious infections, including pneumonia, than those on TNF inhibitors.[3] COVID-19 era studies noted Orencia did not worsen severe respiratory outcomes as much as some biologics, but baseline risk remained higher than non-biologic therapies.[4]
How Does This Compare to Other RA Drugs?
| Drug Class | Pneumonia Risk Relative to Placebo |
|------------|------------------------------------|
| Orencia (T-cell costimulatory modulator) | 1.5-2x higher [2][3] |
| TNF inhibitors (e.g., Humira, Enbrel) | 1.2-1.8x higher [5] |
| Methotrexate alone | 1.1-1.3x higher [5] |
| JAK inhibitors (e.g., Xeljanz) | 2-3x higher, with black-box warnings [6] |
Orencia's risk profile sits in the middle among biologics, lower than JAKs but similar to or slightly above TNFs.
Who Faces the Highest Risk?
Smokers, those over 65, patients with COPD, diabetes, or prior lung disease see amplified risks—up to 3-4x higher pneumonia rates.[2][7] Orencia's label advises screening for latent TB and avoiding in active infections.[1]
What Warnings Are on the Label?
FDA black-box warning covers serious infections leading to hospitalization or death, explicitly listing pneumonia. Discontinue if serious lung infection develops.[1] EMA label echoes this, noting dose-dependent risk.[8]
Can You Lower the Infection Risk?
Pneumococcal and flu vaccines are recommended before starting (live vaccines contraindicated during treatment).[1] Prophylactic antibiotics aren't standard, but monitoring for symptoms like cough, fever, or dyspnea is key. Switching to lower-risk therapies may be considered for high-risk patients.[7]
[1]: Orencia Prescribing Information (FDA)
[2]: Orencia Clinical Trials Data (BMS)
[3]: Xie et al., Arthritis Rheumatol 2019
[4]: Yao et al., Lancet Rheumatol 2021
[5]: Singh et al., Cochrane Database Syst Rev 2011
[6]: Xeljanz Label (FDA)
[7]: Listing et al., Ann Rheum Dis 2018
[8]: Orencia EMA Summary (2023)